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Background: Prompt treatment of malaria attacks with arteminisin-based combination therapy (ACT) is an essential
tool for malaria control. A new co-blister tablet of artesunate-mefloquine (AM) with 25 mg/kg mefloquine has been
developed for the management of uncomplicated malaria attacks. This non-inferiority randomized trial, was
conducted to evaluate the efficacy and safety of the new formulation of AM in comparison to
artemether-lumefantrine (AL) for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in
Senegal.
Methods: The study was carried out from September to December 2010 in two health centres in Senegal. The
study end points included (i) PCR corrected adequate clinical and parasitological response (ACPR) at day 28,
(ii) ACPR at days 42 and 63, (iii) parasites and fever clearance time, (iv) incidence of adverse events and patients
biological profile at day 7 using the WHO 2003 protocol for anti-malarial drug evaluation.
Results: Overall, 310 patients were randomized to receive either AM (n = 157) or AL (n = 153). PCR corrected ACPR
at day 28 was at 95.5% in the AM arm while that in the AL arm was at 96.7% (p = 0.83). Therapeutic efficacy was at
98.5% in the AM arm versus 98.2% in the AL group at day 42 (p = 1). At day 63, ACPR in the AM and AL arms was
at 98.2% and 97.7%, respectively (p = 0.32). The two treatments were well tolerated with similar biological profile at
day 7. However, dizziness was more frequent in the AM arm.
Conclusion: Artesunate-mefloquine (25 mg/Kg mefloquine) is efficacious and well-tolerated for the treatment of
uncomplicated P. falciparum malaria in adult patients.Background
Malaria remains a major public health problem in tropical
regions. According to the World Health Organization
(WHO), in 2010 there were an estimated 149 to 274 million
cases and 537,000 to 907,000 deaths worldwide [1]. Over
86% of these deaths occur in children under five years of
age [1]. The development and spread of multidrug-resistant
Plasmodium falciparum, particularly for the previous main
anti-malarial drugs, such as chloroquine and sulphadoxine-
pyrimethamine, has affected efforts to control malaria, and* Correspondence: roger.tine@ucad.edu.sn
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reproduction in any medium, provided the orcan lead to an increase in malaria mortality and mor-
bidity if ineffective drugs remain the standard of care
after drug-resistant strains become established. To
deal with the threat of resistance of P. falciparum to
monotherapies, combinations of anti-malarial drugs
are now recommended by the WHO.
Artemisinin-based combination therapy (ACT) is widely
promoted as a strategy to counteract the increasing resist-
ance of P. falciparum to anti-malarial drugs, prevent
disease transmission and reduce the risk of drug resistance
[2-4]. ACT can rapidly reduce the parasite biomass, and
may also prevent transmission of P. falciparum by acting
against gametocytes [5,6]. Several formulations of ACT. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malaria. A co-blister tablet formulation of artesunate-
mefloquine (ArtequinW) has been developed by Mepha Ltd
and was initially used on the basis of 750 mg mefloquine,
which represents 15 mg/kg mefloquine per treatment.
Studies in Asian countries showed that artesunate-
mefloquine (AM) is effective and safe for the treatment of
uncomplicated malaria [7]. In Africa, several studies
demonstrated its efficacy and tolerability [8,9]. However,
the dosage of 15 mg/kg mefloquine base is below the
posology recommended by the WHO (25 mg/kg mef-
loquine), to avoid resistance to mefloquine. As a line
extension of the co-blister tablet, a co-formulation of
AM was developed for the treatment of paediatric
patients. Following a recent change in recommenda-
tions of WHO for areas of high malaria transmission,
the total mefloquine dosage in the co-blister tablet for-
mulation and the novel paediatric formulation was
increased to 25 mg/kg body weight [2]. Although the
paediatric co-formulation was safe and effective in chil-
dren less than 5 years [10], studies aiming at evaluating
the new co-blister in adults patients have become rele-
vant in the context of scaling up anti-malarial drugs in
African countries, in order to continue to monitor
adverse drug reactions as well as drug efficacy. The aim
of this study was to compare the clinical and parasito-
logical efficacy, as well as the clinical safety, laboratory
profile, of a new formulation of artesunate-mefloquine
(AM) (25 mg/kg mefloquine base) compared to
artemether-lumefantrine (AL) for the treatment of
uncomplicated P. falciparum malaria in adults in Senegal.Methods
Study area and population
The study was carried out from September to December
2010 in the two health centres of Guediawaye (20 km
from Dakar, the capital city), and Kaolack, 200 km
from Dakar (Senegal). Malaria transmission in the
two sites is highly seasonal with a transmission peak
from September to December. Plasmodium falciparum
is the predominant parasite species and transmission is
mainly due to Anopheles gambiae s.l. (Konate et al.
unpublished data).
Adult patients with acute uncomplicated P. falciparum
malaria seen at study sites with parasite density ranging
from 1,000 to 100,000 parasites/μL, and presence of an
axillary temperature >37.5°C or history of fever during
the previous 24 hours, were included in the study.
Patients were excluded if they had signs of severe
malaria such as convulsions, severe anaemia, respiratory
distress, jaundice, haemoglobinuria or/and had a history
of allergy to the study drugs. Informed consent was
required prior to each study participant enrolment.Study design
The study was designed as an open randomized, non-
inferiority trial with two parallel groups, comparing three-
day regimens of AM versus AL. The primary end point
was represented by the PCR corrected adequate clinical
and parasitological response at day 28. Secondary end
points were represented by (i) adequate clinical and
parasitological response at days 42 and 63, (ii) parasites
and fever clearance time, (iii) incidence of adverse events
in the two groups, (iv) patients’ biological profile at day 7
in the two groups.
Treatment
Patients in the AM arm received one tablet of artesunate
(200 mg) and one tablet of mefloquine (500 mg) everyday
for three days, representing a total dose of 600 mg of arte-
sunate and 1,500 mg of mefloquine. In the AL arm,
patients received four tablets twice daily for three days.
Each tablet of AL contains 20 mg of lumefantrine and
120 mg of artemether. Treatment doses were adminis-
tered at health centres under the supervision of the study
physician. In the event of a patient vomiting within
30 minutes of tablet intake, the dose was repeated. In the
event of a second vomiting episode, the patient was
withdrawn and received quinine in accordance with the
national malaria control programme guidelines.
Data collection
The WHO 2003 protocol for anti-malarial drug efficacy
evaluation was used in this study [11]. After inclusion,
patients were evaluated every day during treatment (days
0, 1, 2), on day 3 and at follow up on days 7,14,21, 28. In
a subgroup of randomly selected study participants
(representing 30% of the total sample), the follow up was
extended at days 42 and 63 to assess the long term pro-
tective effect of each drug after curative doses. During
each scheduled visit, patients were interviewed and
examined by the study physician to assess their clinical
conditions as well as adverse events. All signs noted during
the interview and clinical examinations were reported on a
case reported form (CRF). Thick and thin smears
were performed at each scheduled visit; four drops of
blood were collected on filter paper at Day 0 and at
day of recurrent parasitaemia for genotyping in order
to distinguish recrudescence from new infection.
Laboratory methods
Thick and thin smears
Blood samples were collected using finger prick blood.
Thick and thin smears were stained with Giemsa. Parasite
density was determined by counting the number of
asexual parasites per 200 white blood cells, and calculated
per μL using the following formula: numbered parasites ×
8,000/200 assuming a white blood cell count of 8,000 cells
Table 1 Primer sequence and polymerase chain reaction (PCR) program for MSP1 and MSP2 amplification
Gene Name Primer sequence PCR program
msp 1 primary O1 50 CACATGAAAGTTATCAAGAACTTGTC 30 94°C-3 min, [94°C-25 sec, 50 °C-45 sec, 68°C-2 min] × 30, 72°C-3 min
O2 50 GTACGTCTAATTCATTTGCACG 30
msp 1 nested N1 50 GCAGTATTGACAGGTTATGG 30 94°C-3 min, [94°C-30 sec, 50 °C-45 sec, 68°C-2 min] × 30, 72°C-3 min
N2 50 GATTGAAAGGTATTTGAC 30
msp2 primary S3 50 GAAGGTAATTAAAACATTGTC 30 94°C-3 min, [94°C-30 sec, 420C-60 sec, 65°C-2 min] × 30, 72°C-3 min
S2 50 GAGGGATGTTGCTGCTCCACAG 30
msp2 nested S1 50 GAGTATAAGGAGAAGTATG 30 94°C-3 min, [94°C-30 sec, 50 °C-60 sec, 72°C-2 min] × 45, 72°C-3 min
S4 50 CTAGAACCATGCATATGTCC 30
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ocular fields of the thick film was considered as negative.
The slide readers were kept blinded to the treatment
allocated and day of visit.
Haematological and biochemistry analysis
Haematological and biochemical tests were performed at
enrolment and at Day 7 to evaluate haemoglobin concen-
tration, creatinine, aspartate amino transferase (ASAT), ala-
nine aminotransferase (ALAT), and bilirubin concentration.
Biological abnormalities were noted.
Genotyping
PCR analysis was done to distinguish recrudescence
from new infection. Nested polymerase chain reactionFigure 1 Patients’ trial profile.(PCR) was conducted to compare two polymorphic
genetic markers from P. falciparum msp1 and msp2
genes [12]. After DNA extraction, PCR was performed
using primer pairs. Two microlitres of DNA in a total of
50 μL of reaction mixture were amplified during the pri-
mary PCR using the programme shown in Table 1. One
microlitre of the product of the first amplification in a
total of 50 μL of reaction mixture was used for the sec-
ond PCR with the second programme. Each reaction
mixture contained 10 μL of buffer/MgCl2 (3.5 mM), 5
μL of dNTP (200 mM), 0.5 μL of each primer (100 μM),
0.25 μL of Taq polymerase (0.5 units), and 32.25 μL of
distilled DNA-free water. The DNA was added last.
Amplification products were visualized by photography
under ultraviolet light after electrophosis on 1.5%
Table 2 Baseline characteristics of patients at enrolment in the two groups
Artesunate Mefloquine (n = 157) Artemether Lumefantrine (n = 153) p value
Age (mean ± SD, years) 25 ± 11 23.2 ± 10,5 0.15
Weight (mean ± SD, Kg) 62.1 ± 11.8 58.2 ± 11.5 0.08
Sex ratio (male/female) 1.2 0.6 0.03
Temperature (mean ± SD) 37.8 ± 1.2 37.7 ± 1.1 0.41
Median Parasitemia (trophozoites/μL) 17411 17688 0.88
Mean haemoglobin (g/dl) 12.2 ± 1.7 11.7 ± 1.7 0.99
Anaemia (Hb < 11 g/dl,%) 36.3 40.5 0.44
ASAT (UI/L, mean ± SD) 31.2 ± 18.7 33.1 ± 16.8 0.38
Patients with normal level of ASAT (ASAT < 40 UI/L) (%) 128 (81.5%) 123 (80.4%) 0.79
ALAT (UI/L, mean ± SD) 28.2 ± 20.3 26.3 ± 24.1 0.47
Patients with normal level of ALAT (ALAT < 40 UI/L) (%) 119 (82.1%) 138 (90.2%) 0.04
Creatinine (mean ± SD) 7.6 ± 5.4 8.2 ± 3.5 0.24
Patients with normal level of creatinine (<13 mg/L) (%) 148 (94.3%) 143 (93.5%) 0.76
Median Bilirubunemia (mg/L) 1.91 1.71 0.51
Patients with normal level of Biliribunemia (<10 mg/L) (%) 48 (30.6%) 55 (35.9%) 0.31
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agarose for msp2.
The difference in fragment size between pre-treatment
and post-treatment samples allows a classification in
three categories: new infection if the fragment sizes are
different, recrudescence if the fragment sizes are similar,
and both recrudescence and new infection if two frag-
ments are visualized in the post-treatment sample with
one similar to the pre-treatment fragment. The last two
are considered as recrudescence for the analysis [13].
Statistical methods
The number of subjects to be included in this study was
calculated using STATA-11™ software, based on an
expected therapeutic efficacy of AL at 98% [8] assuming
a non-inferiority margin of 7% and 80% of power, usingFigure 2 Kaplan Meir survival estimates of PCR adjusted ACPR
by treatment arm – ITT analysis.a 95% confidence level, sample size for each arm was
evaluated at 160 patients. Data were entered in Excel™
software and analysed using STATA-11™ software.
Characteristics of all patients included in the study were
tabulated by study arm. For categorical data, percentage
was used to assess the frequency of each outcome. For
continuous data, mean and standard deviation were used
to describe normally distributed variables; otherwise
median and range were used. For the primary end point
of adequate clinical and parasitological response at day
28, analysis was done by intention to treat and per
protocol. The intention treat analysis included all rando-
mized patients, while in the per protocol analysis,
patients who were not seen at day 28 were excluded.
The ACPR at day 28 was calculated for each study arm
and compared using chi square test. The cumulative
incidence of failure rate was calculated in each study
arm and compared using Kaplan Meir method. For the
ACPR at days 42 and 63, analysis was done by per protocol
and comparison was made in a similar way.
The frequency of adverse events was described in
terms of proportion in each study arm. For some
adverse events such as dizziness, analysis was adjusted
by haemoglobin level at inclusion, gender, age group
and study arm. A stepwise logistic regression was
done for the determination of factors associated with
dizziness. Significance level of tests was set on 0.05
two side.
Ethical considerations
The protocol was reviewed and approved by the Conseil
National de Recherche en Santé (CNRS), which is the
Senegalese national ethics committee. On the field,
Table 3 Therapeutic efficacy of AM and AL at days 28, 42 and 63 in adult patients in Senegal – IIT and PP analysis
Outcome Artesunate Mefloquine (n = 157) Artemether Lumefantrine (n = 153) p value
Intention to treat analysis
Early treatment failure 00 00 -
NA 6 (3.82%) 4 (2.61%) 0.77
Crude Parasitological failure at day 28 1 (0.64%) 4 (2.61%) 0.35
PCR adjusted failure rate 1 (0.64%) 1 (0.65%)
PCR adjusted cure rate at day 28 150 (95.54%) 148 (96.73%) 0.58
Artesunate Mefloquine Artemether Lumefantrine
Per protocol analysis
Early treatment failure 00 00 -
Crude parasitological failure 1/151 (0.66%) 4/149 (2.6%) 0.17
PCR adjusted failure rate 1/151 (0.66%) 1/149 (0.67%) 0.99
PCR adjusted cure rate at day 28 150/151 (99.34%) 148/149 (99.33%) 0.99
Crude parasitological failure at day 42 2/70 (2.8%) 5/57 (8.7% 0.20
PCR adjusted ACPR at day 42 69/70 (98.5%) 56/57 (98.2%) 1
Crude parasitological failure at day 63 4/57 (7%) 6/44 (13%) 0.32
PCR adjusted ACPR at day 63 56/57 (98.2%) 43/44 (97.7%) 1
NA = Not applicable.
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prior to their enrolment.
Results
Baseline characteristics
Overall 410 individuals participated to the screening,
and 310 of them meet the entry criteria. Patients’ trial
profile is summarized in Figure 1. A total number of 310
patients, 157 in the AM arm and 153 in the AL arm
were thus recruited in the study. At enrolment, patient
characteristics were similar in the two study arms. No
significant difference was noted in terms of age, axillary
temperature, parasitaemia at inclusion, mean haemoglo-
bin as well as biochemical parameters such as creatinine,
ASAT, ALAT and bilirubin. Patient baseline characteris-
tics are summarized in Table 2.
Treatment efficacy
In the intention to treat analysis, PCR corrected ad-
equate clinical parasitological response (ACPR) at day 28Table 4 Incidence of adverse events in the two study groups
Day 1 Day 2
Adverse event AM AL AM
Dizziness (n,%) 35 (22.3) 17 (11.1) 61 (38.8)
Vomit (n,%) 16 (10.2) 11 (7.2) 09 (5.7)
Abdominal pain 15 (9.5) 11 (7.2) 11 (7.2)
Pruritus (n,%) 0 2 (1.3) 0
Oral herpes (n,%) 0 2 (1.3) 0
AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.(primary end point), was evaluated at 95.5% in the AM
arm versus 96.7% in the AL arm (p = 0.58) (difference
−0.01 (95%CI [−0.05;0.03]). In the per protocol analysis,
the PCR adjusted ACPR was estimated at 99.33% in the
AM arm versus 99.34% in the AL arm (p = 0.99) (differ-
ence 0.0008 95%CI [−0.018; 0.018]). In addition, the
Kaplan-Meier PCR adjusted analysis did not show any
significant difference between the two treatment groups
in terms of cumulative incidence of failure rate, up to
day 28 (log rank test, p = 0.67) (Figure 2). Thus, the non-
inferiority of AM versus AL was demonstrated both in
intention to treat and per protocol analysis (Table 3).
For the 104 patients, representing 30% of the total
sample, (57 AM arm and 57 AL arm) seen at day 42, the
PCR adjusted ACPR was 98.5%% and 98.2%, respectively,
in the AM and AL groups (Table 3). Overall, 57 patients
in the AM arm and 44 patients in the AL arm attended
the day 63 visit. PCR adjusted ACPR at day 63 was
evaluated at 98.2%% in the AM arm versus 97.7% in the
AL arm (p = 1) (Table 3).from inclusion to day 7 of follow up
Day 3 Day 7
AL AM AL AM MF
8 (5.2) 58 (38.1) 11 (7.1) 15 (10.2) 6 (4.03)
0 04 (2.6) 0 0 0
10 (6.5) 10 (6.5) 4 (2.6) 1 (0.66) 0
1 (0.6) 0 0 0 0
3 (1.9) 1 (0.66) 3 (1.9) 0 1 (0.67)
Table 5 Frequency of dizziness by study group adjusted by gender, age, anaemia at inclusion
Dizziness
Day 1 Day 2 Day 3
n (%) aOR** (95%CI) p value n (%) aOR (95%CI) p value n (%) aOR (95%CI) p value
*Treatment
AL (n = 153) 17 (11.1%) 1 8 (5.2) 1 11 (7.1) 1
AM (n = 157) 35 (22.3%) 2.2 (1.1-4.4) .02 61 (38.8) 12.5 (5.5 – 28.1) .001 58 (38.1) 10.2 (4.7-22.3) .001
* AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.
**aOR: adjusted odds ratio. The analysis of the association between dizziness and treatment was adjusted by mean haemoglobin at inclusion, age, gender.
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ments groups. Following the first treatment dose (at day
0), 2.6% of patients in the AM arm were found with
fever (temperature >37.5 °C) while 5.3% of patients in
the AL arm were febrile after the first treatment day
(p = 0.25). At day 2, all patients both in the AM arm
and AL were found without fever.
The two treatments resulted in a rapid clearance of
parasites. The mean parasitaemia at enrolment was
17,411 trophozoites/μL in the AM group and 17,688
in the AL group. It decreased to 864 trophozoites/μL
in the AM group versus 949 trophozoites/μL in the
AL group, 24 hours after the first dose (p = 0.28).
Complete parasite clearance was obtained at Day 2 in
the two treatment arms.Table 6 Patients’ biological profile at day 7 post
treatment
AM AL p value
Day 7 Day 7
Mean haemoglobin 11.3 ± 1.8 10.6 ± 1.5 0.11
Anaemia (%) 86 (54.7%) 105 (68.6%) 0.01
Median ALAT 19 19.3 0.93
Median ASAT 24 25 0.53
Patients with ASAT < 40 (%) 143 (91%) 139 (90.8%) 0.94
Patients with ALAT < 40 (%) 146 (92.9%) 145 (94.7%) 0.51
Mean creatinine 7.7 ± 4.7 8.2 ± 7.0 0.50
Patients with normal
level of creatinine (%)
149 (94.9%) 150 (98.0%) 0.13
Median bilirubin 1.10 1.08 0.36
Patients with normal
level of bilirubin (%)
92 (58.6%) 82 (53.6%) 0.37Safety and tolerability
Overall, the two treatments were well tolerated. No
serious adverse event was observed during the study
period. The main observed adverse events, were dizzi-
ness, abdominal pain, vomiting, diarrhoea and prur-
itus (Table 4). Dizziness were more frequent in the
AM arm (22.9%) than in the AL arm (11.1%) (p = 0.008).
After controlling for confounding factors such as
presence of anaemia at enrolment, age and gender,
dizziness was closely associated with AM intake.
Indeed, the adjusted odds ratio after the first dose of
AM was 2.3 (95%CI 1.1-4.4; p = 0.02); an increased
risk of dizziness was also found after the second dose of
AM (aOR = 12.5; 95%CI 5.5-28.1; p = 0.001) and after the
third dose (aOR = 10.2; 95%CI 4.7-22.3; p = 0.001)
(Table 5).
Overall, patients’ biological profile was similar in
the two treatments groups. Haemoglobin level was
lower at day 7 in both AM and AL groups compared
to haemoglobin level at inclusion in each study arm.
Anaemia was more frequent at day 7 in the AL arm
(68.6%) than in the AM arm (54.7%) (p = 0.01). An
increased level of anaemia was observed in the two
treatment groups at day 7 compared to the proportion of
anaemic patients at enrolment. No significant difference
was noted between the two treatment groups at day 7 interm of ALAT and ASAT level as well as bilirubin
and creatinine concentration (Table 6).Discussion
Prompt treatment of malaria attacks with effective anti-
malarial drug combination is an essential tool for
malaria control. Malaria attacks treatment requires the
use of artemisinin-based combination therapy (ACT).
This non-inferiority randomized trial, evaluated the
efficacy and safety of a new formulation of AM with
25 mg/kg mefloquine in comparison to AL. Results
from this trial indicated that AM is as effective and
well-tolerated as AL for the treatment of acute uncompli-
cated P. falciparum malaria in adults’ patients. Indeed, the
PCR corrected ACPR at day 28 was 95.5% in the AM arm
as against 96.7% in the AL arm; similar results were
obtained in the per protocol analysis with a PCR corrected
ACPR at 99.3% and 97.3%, respectively, in the AM
and AL group.
These findings are consistent with data described in
other trials conducted in African countries. Faye et al. in
Senegal obtained a cure rate of 96.2% at day 28 when
AM was administrated to children less than five years in
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reported a cure rate of 96% at day 28 for AM and 92%
for AL [14], while Sowunmi et al. reported a therapeutic
efficacy at 97% for AM and 94% for AL at day 28 in
Nigerian children [15]. In patients seen at days 42 and
63 of follow up, PCR adjusted cure rate was evaluated at
98.5%% at day 42 and 98.2% at day 63 for AM group
while that for the AL arm was at 98.2% at day 42 and
97.7% at day 63. Thus, the two treatments were highly
effective at day 42 and 63 of follow up. Pharmacokinetics
studies have demonstrated the long half-life of meflo-
quine and its ability to reduce rates of reinfection
[16]. However, due to the low number of patients
seen at day 42 and day 63, the study has lacked of
power at day 42 and 62. Further studies with larger
sample size would thus provide additional evidence
on the long- term effect of mefloquine.
The two treatments were effective in reducing the
parasite biomass as well as fever [5,6]. Thus, on day 2 a
complete fever clearance was obtained in the two
groups. Similarly, all study participants had a complete
parasite clearance at day 2.
The two treatments were well tolerated with a similar
safety profile. No serious adverse event was reported
during the trial. However, dizziness was more frequent
in patients treated with AM. The risk of dizziness in
patients treated with AM was dose-related. Indeed, an
increase risk was observed after each treatment course
(aOR at day 1 = 2.3, aOR at day 2 = 12, aOR at day 3 = 10).
Several reviews have published data on the neuro-
psychiatric effects of mefloquine. In more than 25,000
patients involved in about 20 trials, dizziness and
anxiety were the most commonly reported adverse
events in adult patients [17-19] as well as vomiting,
especially in young children [20-22]. However, despite
the frequency of dizziness during the study, no major
biological disorder was noted in the study participants
and therapeutic efficacy remains good in the two
treatment groups. The use of the new formulation of
AM should be combined with regular counselling in
order to improve patient’s compliance.
Conclusion
The new formulation of artesunate-mefloquine (25 mg/Kg
mefloquine) is efficacious and well-tolerated for the
treatment of uncomplicated P. falciparum malaria in
adult patients.
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